Press Releases

MGEN $6.78 $ - 0.49 (6.74%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
6/4/2018
7:30 AM ET
Press Release

Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting

6/4/2018

First two patients with aggressive forms of adult T-cell leukemia/lymphoma treated with cobomarsen demonstrated greater than five months of clinical response with improvement in objective disease meas...

 Continue Reading
5/31/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th

5/31/2018

BOULDER, Colo., May 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapi...

 Continue Reading
5/16/2018
5:00 PM ET
Press Release

miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting

5/16/2018

BOULDER, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapi...

 Continue Reading
5/9/2018
4:05 PM ET
Earnings Release

miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update

5/9/2018

MRG-110 advanced into clinical development with the initiation of two Phase 1 clinical trials in collaboration with ServierPreclinical data released in two separate ophthalmology programs targeting mi...

 Continue Reading
5/8/2018
4:05 PM ET
Press Release

miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides

5/8/2018

Treatment resulted in durable improved quality of lifeCobomarsen continued to be generally well tolerated at all dose levels evaluatedAdvancing into a Phase 2 clinical trial in second half of 2018BOUL...

 Continue Reading
Displaying 1 to 5 (of 55 releases)